Dirk Blom

17.6k total citations · 9 hit papers
159 papers, 8.1k citations indexed

About

Dirk Blom is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Economics and Econometrics. According to data from OpenAlex, Dirk Blom has authored 159 papers receiving a total of 8.1k indexed citations (citations by other indexed papers that have themselves been cited), including 127 papers in Surgery, 53 papers in Endocrinology, Diabetes and Metabolism and 44 papers in Economics and Econometrics. Recurrent topics in Dirk Blom's work include Lipoproteins and Cardiovascular Health (122 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (41 papers) and Cancer, Lipids, and Metabolism (35 papers). Dirk Blom is often cited by papers focused on Lipoproteins and Cardiovascular Health (122 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (41 papers) and Cancer, Lipids, and Metabolism (35 papers). Dirk Blom collaborates with scholars based in South Africa, United States and France. Dirk Blom's co-authors include Frederick J. Raal, Scott M. Wasserman, A. David Marais, Robert C. Scott, Evan A. Stein, Michael J. Koren, Daniel Gaudet, Christie M. Ballantyne, Robert P. Giugliano and Marc S. Sabatine and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Circulation.

In The Last Decade

Dirk Blom

148 papers receiving 7.9k citations

Hit Papers

Efficacy and Safety of Evolocumab in Reducing Lipids and ... 2010 2026 2015 2020 2015 2010 2014 2014 2012 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
    2015 1.1k citations Marc S. Sabatine, Robert P. Giugliano et al. New England Journal of Medicine profile →
  2. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
    2010 692 citations Frederick J. Raal, Dirk Blom et al. The Lancet profile →
  3. A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
    2014 553 citations Dirk Blom, R Češka et al. New England Journal of Medicine profile →
  4. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial
    2014 553 citations Frederick J. Raal, Narimon Honarpour et al. The Lancet profile →
  5. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study
    2012 524 citations Marina Cuchel, Emma A. Meagher et al. The Lancet profile →
  6. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia
    2015 418 citations John J.P. Kastelein, Henry N. Ginsberg et al. European Heart Journal profile →
  7. Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome
    2019 416 citations Daniel Gaudet, Fernando Civeira et al. New England Journal of Medicine profile →
  8. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial
    2015 316 citations Christopher P. Cannon, Dirk Blom et al. European Heart Journal profile →
  9. Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)
    2014 281 citations Frederick J. Raal, Robert P. Giugliano et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dirk Blom South Africa 36 6.3k 2.2k 2.0k 1.9k 1.6k 159 8.1k
A. David Marais South Africa 35 3.5k 0.6× 1.5k 0.7× 1.2k 0.6× 480 0.3× 1.2k 0.7× 130 5.0k
Marcello Arca Italy 43 2.9k 0.5× 2.1k 0.9× 2.1k 1.0× 360 0.2× 1.1k 0.7× 215 6.3k
David Kallend United States 36 5.4k 0.9× 2.6k 1.1× 1.8k 0.9× 1.2k 0.6× 1.5k 0.9× 99 7.8k
Pedro Mata Spain 36 2.7k 0.4× 1.0k 0.5× 830 0.4× 517 0.3× 934 0.6× 119 4.0k
Marlys L. Koschinsky Canada 53 6.1k 1.0× 1.9k 0.8× 2.5k 1.2× 341 0.2× 2.4k 1.5× 190 9.4k
Marina Cuchel United States 26 3.3k 0.5× 2.3k 1.0× 1.2k 0.6× 218 0.1× 1.2k 0.7× 81 5.0k
David W. Bilheimer United States 35 4.7k 0.7× 2.2k 1.0× 1.3k 0.7× 411 0.2× 1.8k 1.1× 61 7.5k
John R. Burnett Australia 36 2.5k 0.4× 1.3k 0.6× 956 0.5× 287 0.2× 694 0.4× 164 4.6k
Gilbert R. Thompson United Kingdom 43 4.1k 0.7× 2.2k 1.0× 1.3k 0.6× 270 0.1× 1.2k 0.8× 172 6.1k
Peter Wijngaard United States 21 2.9k 0.5× 781 0.3× 814 0.4× 740 0.4× 744 0.5× 46 4.9k

Countries citing papers authored by Dirk Blom

Since Specialization
Citations

This map shows the geographic impact of Dirk Blom's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dirk Blom with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dirk Blom more than expected).

Fields of papers citing papers by Dirk Blom

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dirk Blom. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dirk Blom. The network helps show where Dirk Blom may publish in the future.

Co-authorship network of co-authors of Dirk Blom

This figure shows the co-authorship network connecting the top 25 collaborators of Dirk Blom. A scholar is included among the top collaborators of Dirk Blom based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dirk Blom. Dirk Blom is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tromp, Tycho R., M. Doortje Reijman, Laurens F. Reeskamp, et al.. (2025). Real-world family planning and pregnancy practices in women with homozygous familial hypercholesterolemia. Atherosclerosis. 404. 119187–119187.
2.
Raal, Frederick J., Vimal Mehta, Meral Kayıkçıoğlu, et al.. (2025). Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial. The Lancet Diabetes & Endocrinology. 13(3). 178–187. 6 indexed citations
3.
Tromp, Tycho R., et al.. (2025). Global disparities in access to lipid-lowering therapies for patients with homozygous familial hypercholesterolemia – A physician survey. Journal of clinical lipidology. 19(4). 1009–1019. 2 indexed citations
4.
5.
6.
Underberg, James, Christopher P. Cannon, Dominique Larrey, et al.. (2024). The Lomitapide Observational Worldwide Evaluation Registry (LOWER) - Nine-year Effectiveness and Safety Data in HoFH. Journal of clinical lipidology. 18(4). e545–e545.
7.
Blom, Dirk, Erika Jones, Brian Rayner, et al.. (2023). Major Genetic Drivers of Statin Treatment Response in African Populations and Pharmacogenetics of Dyslipidemia Through a One Health Lens. OMICS A Journal of Integrative Biology. 28(6). 261–279. 1 indexed citations
8.
9.
Preiss, David, Naveed Sattar, J Robinson, et al.. (2015). Efficacy of one year of treatment with the PCSK9 inhibitor evolocumab (AMG 145) in 4,802 subjects with or without type 2 diabetes. Diabetologia. 58.
10.
Sabatine, Marc S., Robert P. Giugliano, Stephen D. Wiviott, et al.. (2015). Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events. New England Journal of Medicine. 372(16). 1500–1509. 1091 indexed citations breakdown →
11.
Preiss, David, Dirk Blom, C. Stephen Djedjos, et al.. (2015). Evaluation of the one-year efficacy, safety and glycaemic effects of evolocumab (AMG 145) in 4,802 subjects with, at high risk for, or at low risk for, diabetes mellitus. Diabetologia. 58. 6 indexed citations
12.
Kastelein, John J.P., Henry N. Ginsberg, Gisle Langslet, et al.. (2015). ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. European Heart Journal. 36(43). ehv370–ehv370. 418 indexed citations breakdown →
13.
Raal, Frederick J., Marja‐Riitta Taskinen, Colin Schamroth, et al.. (2015). South African Dyslipidaemia Guideline Consensus Statement. SHILAP Revista de lepidopterología. 57(2). 9–9. 2 indexed citations
14.
Raal, Frederick J., Narimon Honarpour, Dirk Blom, et al.. (2014). Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. The Lancet. 385(9965). 341–350. 553 indexed citations breakdown →
15.
Cuchel, Marina, Dirk Blom, Maurizio Averna, et al.. (2013). Abstract 16516: Sustained LDL-C Lowering and Stable Hepatic Fat Levels in Patients With Homozygous Familial Hypercholesterolemia Treated With the Microsomal Triglyceride Transfer Protein Inhibitor, Lomitapide: Results of an Ongoing Long-Term Extension Study. Circulation. 11 indexed citations
16.
Cuchel, Marina, Emma A. Meagher, Dirk Blom, et al.. (2012). Abstract 17396: Apheresis Treatment does not Affect the Lipid-Lowering Efficacy of Lomitapide, a Microsomal Triglyceride Transfer Protein Inhibitor, in Patients with Homozygous Familial Hypercholesterolemia. Circulation. 126. 3 indexed citations
17.
Blom, Dirk. (2011). Familial hypercholesterolaemia : CPD article. South African Family Practice. 53(1). 11–18. 1 indexed citations
18.
Blom, Dirk & Adéle Marais. (2009). New therapeutic developments in lipidology. CME/Continuing medical education. 27(3). 104–106. 1 indexed citations
19.
Cuchel, Marina, Emma A. Meagher, A. David Marais, et al.. (2009). Abstract 1077: A Phase III Study of Microsomal Triglyceride Transfer Protein Inhibitor Lomitapide (AEGR-733) in Patients With Homozygous Familial Hypercholesterolemia: Interim Results at 6 Months. Circulation. 120. 4 indexed citations
20.
Blom, Dirk, et al.. (2008). Severe Hypertriglyceridaemia as a result of Familial Chylomicronaemia. South African Medical Journal. 98(2). 105–108. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by A. David Marais Breakdown of academic impact, for papers by Marcello Arca Breakdown of academic impact, for papers by David Kallend Breakdown of academic impact, for papers by Pedro Mata Breakdown of academic impact, for papers by Marlys L. Koschinsky Breakdown of academic impact, for papers by Marina Cuchel Breakdown of academic impact, for papers by David W. Bilheimer Breakdown of academic impact, for papers by John R. Burnett Breakdown of academic impact, for papers by Gilbert R. Thompson Breakdown of academic impact, for papers by Peter Wijngaard
Rankless by CCL
2026